Richmond, Virginia, Oct. 01, 2024 (GLOBE NEWSWIRE) — Kaléo, a privately-held U.S. pharmaceutical company has announced a redesign of the AUVI-Q® (epinephrine injection, USP) commercial team structure to increase in-office support for healthcare providers. AUVI-Q is a prescription medicine used to treat emergency allergic reactions, including anaphylaxis, in people who are at risk for or who have a history of serious allergic reactions.
“This enhanced commercial structure for AUVI-Q will double the number of representatives providing in-office support to healthcare providers as well as expand our pharmacy support team to ensure providers and patients have easy access to our affordability programs,” said Kaléo Chairman and Chief Executive Officer, Michael Wells. “Increased access to AUVI-Q is important for the 33 million Americans affected by food allergies as it is the only epinephrine product available in three doses for the treatment of anaphylaxis in adults, children, and infants.”
AUVI-Q is about the size of a credit card and thickness of a smartphone and is the only epinephrine product with calm, voice instructions to help guide users through the administration process. AUVI-Q is available in three doses – AUVI-Q 0.3 mg for those weighing 66 pounds (30 kilograms) or more, AUVI-Q 0.15 mg for children weighing between 33 and 66 pounds (15 to 30 kilograms), and AUVI-q 0.1 mg for infants and toddlers weighing 16.5 to 33 pounds (7.5 to 15 kilograms).
While food allergies can be diagnosed at any age, most appear in early childhood1,2 and the AUVI-q 0.1 mg dose is the only FDA approved epinephrine product for infants and toddlers.
AUVI-Q is available to most commercially insured patients for $35 or less while patients with high-deductible plans or without AUVI-Q coverage will pay no more than $150 through ASPN Pharmacies. Patients who do not have commercial insurance and who are experiencing financial difficulties may be able to receive AUVI-Q at no cost through the Kaléo Patient Assistance Program. Additional information on patient eligibility and the terms and conditions can be found at www.auvi-q.com/get-auvi-q/.
Leave a Reply